A Clinical Study Evaluating the Pharmacokinetic Characteristics and Safety of AHB-137 Injection in Participants With Mild to Moderate Liver Dysfunction and Those With Normal Liver Function.

Phase 1 Not yet recruiting 32 enrolled Ausper Biopharma Co., Ltd.

Non-randomizedParallel-groupOpen-labelTreatment

Summary

A clinical study evaluating the pharmacokinetic characteristics and safety of AHB-137 injection in participants with mild to moderate liver dysfunction and those with normal liver function.

Timeline

Start: 2026-05-15
Primary completion: 2028-05-15
Completion: 2028-05-15

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	AHB-137	Antisense oligonucleotide	—	Subcutaneous

A Clinical Study Evaluating the Pharmacokinetic Characteristics and Safety of AHB-137 Injection in Participants With Mild to Moderate Liver Dysfunction and Those With Normal Liver Function.

Summary

Timeline

Drugs

Indications